Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 2 Interventions and outcomes of included studies
From: Ilizarov bone transport and treatment of critical-sized tibial bone defects: a narrative review
Author/s | Technique | Bone union rate (%) | Bone results (ASAMI, PALEY) (excellent/good/fair/poor) | Functional results (ASAMI, PALEY) (excellent/good/fair/poor) | Complications (per patient) | EFT (months) | EFI (months/cm) |
|---|---|---|---|---|---|---|---|
Madhusudhan et al. | RD/AT/ACL (IEF) | 100 | 5/8/5/4 | 1/4/6/10a | 2.73 (60/22) | 9.3 | 2.33 |
Pirwani et al. | RD/AT/BT (IEF) | 100 | nr | nr | 2 (32/16) | 16 | 3 |
Bumbasirevic et al. | RD/AT/BT (IEF) | 96.6 | 19/10/0/1 | 13/14/2/1 | 1.4 (42/30) | 9.7 | 1.48 |
Megas et al. | RD/AT/CO or ACL | 100 | 5/4/0/0 | 3/4/2/0 | 1.89 (17/9) | 7.83 | 1.07 |
Lin et al. | RD/AT/BT (IEF) | 93.7 | nr | nr | 1 (16/16) | 4.5 | nr |
Babar et al. | RD/AT/BT (IEF) | 97 | 13/2/2/0 | 10/4/2/1 | 1 (17/17) | 6 | nr |
Feng et al. | RD/AT/BT (IEF) | 100 | 19/2/0/0 | nr | 0.4 (8/21) | 9.8 | 1.48 |
Krappinger et al. | RD/AT/BT (IEF) | 80 | 7/6/2/0 | 6/7/2/0 | 3 (45/15) | 13.2 | nr |
Selim | RD/AT/BT (IEF) | 80 | 7/3/0/0 | 7/3/0/0 | 0.7 (7/10) | 2.5 | 0.28 |
Shadid et al. | RD/AT/ACL (IEF) | 100 | 10/2/0/0 | 6/4/2/0 | 0.25 (3/12) | nr | nr |
Spiegl et al. | RD/AT/BT (IEF) | 96 | nr | nr | 1.36 (34/25) | 23.2 | 1.9 |
Xu et al. | RD/AT/BT (IEF) | 100 | 28/2/0/0 | nr | 0.27 (8/30) | 10 | 1.36 |
Yin et al. | RD/AT/BT (IEF) | 100 | 44/15/5/2 | 24/26/10/0b | 1.1 (73/66) | 9.4 | 1.38 |
Morsy | RD/AT/BT (IEF) | 100 | 8/3/0/1 | 7/4/1/0 | 1.58 (19/12) | 6.8 | 1.52 |
Marais et al. | RD/AT/BT (IEF | 100 | nr | nr | 1.57 (11/7) | 17.7 | 2.7 |
Azzam et al. | RD/AT/BT (IEF) | 100 | 22/6/1/1 | 13/9/7/1 | 1.7 (51/30) | 7.5 | 1.3 |
Bernstein et al. | RD/AT/BT (IEF) | 77 | nr | nr | 0.77 (17/22) | 11.03 | 2.5 |
Khan et al. | RD/AT/CO or ACL (IEF) | 95.7 | 6/14/1/2c | 8/12/2/1c | 0.5 (12/24) | 8 | 4.2 |
Peng et al. | RD/AT/BT (IEF) | 100 | 30/23/5/0 | 28/18/12/0 | 0.67 (39/58) | 10.6 | 1.2 |
Wani et al. | RD/AT/BT (IEF) | 100 | 13/9/4/0 | 9/11/5/1 | 2 (52/26) | 14.07 | 1.6 |
Aboumira et al. | RD/AT/BT (IEF) | 89 | 11/8/3/3 | 11/9/2/3 | 0.72 (18/25) | 11.8 | 2.1 |
Aktuglu et al. | RD/AT/BT (IEF) | 95.8 | 12/8/2/2 | 14/9/1/0 | 1 (24/24) | 11.52 | 1.73 |
Fürmetz et al. | RD/AT/BT (IEF) | 100 | nr | nr | nr | 9.52 | 1.47 |
Rohilla et al. | RD/AT/BT (IEF) | 94 | 19/13/0/3 | 14/19/1/1 | 1.2 (42/35) | 11.9 | 1.8 |
Tetsworth et al. | RD/AT/BT or ACL (IEF) | 100 | 15/5/1/0 | 14/6/1/0 | 3.1 (nr) | 12.5 | 1.8 |
Yilihamu et al. | RD/AT/BT (IEF) | nr | nr | nr | 1.46 (21/14) | 9.8 | 1.51 |
Zhang et al. | RD/AT/BT (IEF) | 100 | 10/0/0/6 | 12/4/0/0 | 1.18 (19/16) | 12 | 1.1 |